The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Open accessAbstract
Gene therapy using adeno-associated viral (AAV) vectors currently represents the most promising approach for the treatment of many inherited retinal diseases (IRDs), given AAV’s ability to efficiently deliver therapeutic genes to both photoreceptors and retinal pigment epithelium, and their excellent safety and efficacy profiles in humans. However, one of the main obstacles to widespread AAV application is their limited packaging capacity, which precludes their use from the treatment of IRDs which are caused by mutations in genes whose coding sequence exceeds 5 kb. Therefore, in recent years, considerable effort has been made to identify strategies to increase the transfer capacity of AAV vectors. This review will discuss these new developed strategies, highlighting the advancements as well as the limitations that the field has still to overcome to finally expand the applicability of AAV vectors to IRDs due to mutations in large genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adjustments, such as 200-300 bp of specific compatible overhangs, have resulted in normal concatemerization of independent gene cassettes such as the hybrid dual rAAV approach [214].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“In this context, localized subretinal delivery of therapeutic transgenes has demonstrated efficient photoreceptor engagement using AAV5,7,8 and 9 [126].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [126]
In the citing paper
“The dual AAV vector system involves splitting the large transgene into two <5kb fragments that are packaged and co-delivered into the cell.”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [80]
In the citing paper
“The DNA fragments are then recombined into a complete functional transgene intracellularly either by homologous recombination or trans-splicing mechanisms [79,80,81].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [80]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150 · cited 1×
“First, in the retina, where homologous recombination occurs at low rates, genome editing tools for the precise correction of a mutation will most probably need to exploit alternative repair mechanisms such as non-homologous end joining used for homology-independent targeted integration [61].”
BackgroundEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 1×
“Some studies have shown that use of capsid-engineered AAV variants with higher retinal transduction abilities, as tyrosine mutants capsids [39], led to higher levels of transgene expression from overlapping dual AAV vectors compared to naturally occurring AAV serotypes [20,33].”
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36612 · Cited by 389 · cited 1×
“, a minigene), has also been achieved with some success [58].”
BackgroundStargardt disease: clinical features, molecular genetics, animal models and therapeutic options
Tanna, P., Strauss, R. W., Fujinami, K., & Michaelides, M. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308823 · Cited by 370 · cited 1×
“The efficacy of both oversized and dual AAV vectors in the retina has been evaluated in a number of studies using different reporter and therapeutic genes, such as ABCA4 and MYO7A mutated in Stargardt disease (STGD1) [31] and Usher syndrome type 1B (USH1B) [32], respectively.”
BackgroundIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310 · cited 2×
“AAV5, AAV7, AAV8 and AAV9 serotypes have all been demonstrated to efficiently transduce photoreceptors [4,8].”
ResultTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · cited 2×
“The trans-splicing approach relies on the natural ability of AAV ITRs to concatemerize in order to reconstitute full-length genomes [22,25].”
Background
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“With dual AAV technology, cDNA fragments that exceed the cargo capacity of a single AAV can be split into two halves and each packaged into a separate AAV, with additional sequences that allow reconstitution of the complete cDNA once inside the target cell (Trapani, 2019).”
BackgroundGhosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218
Gene regulatory programmes of tissue regeneration
Goldman, J. A., & Poss, K. D. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0239-7 · Cited by 200
Usher syndrome: clinical features, molecular genetics and advancing therapeutics
Toms, M., Pagarkar, W., & Moosajee, M. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420952194 · Cited by 133
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
“Therefore, in recent years, considerable effort has been made to identify strategies to increase the transfer capacity of AAV vectors [62].”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
Backgroundde Guimarães, T. A. C., Georgiou, M., Bainbridge, J. W., & Michaelides, M. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316195 · Cited by 99
“34 35 Several strategies have been investigated to bypass this cargo capacity, including directed evolution and the generation of dual AAV vectors.”
BackgroundMolecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Disease mechanisms and gene therapy for Usher syndrome
Géléoc, G. S. G., & El-Amraoui, A. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107932 · Cited by 84
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
“Assessment of the potential of dual AAV vectors in reconstituting both reporter and therapeutic genes in vitro and in vivo has been performed, having as a target various tissues, including sensory organs, 55,56 muscle, 41,57–59 lung, 60 heart, 61 and liver.”
Self-citationBatra, R., Nelles, D. A., Roth, D., Krach, F., Nutter, C. A., Tadokoro, T., Thomas, J. D., Sznajder, Ł. J., Blue, S. M., Gutierrez, H. L., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00607-7 · Cited by 64
“Importantly, both Cas9 and GFP (correlated with sgRNA) RNAs were simultaneously detected in most of these tissues 65,66 (Fig.”
BackgroundMarrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“photoreceptor engagement using AAV5,7,8 and 9 [126].”
Biomedical nanobubbles and opportunities for microfluidics
Paknahad, A. A., Kerr, L., Wong, D. A., Kolios, M. C., & Tsai, S. S. H. (2021) · RSC Advances · doi:10.1039/d1ra04890b · Cited by 61
Development of New Strategies Using Extracellular Vesicles Loaded with Exogenous Nucleic Acid
Orefice, N. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080705 · Cited by 59
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 58
“In parallel, others and us have provided proof-of-concept that large transgenes can be delivered via AAV by splitting them into two separate vectors (dual AAV), which upon co-infection of the same cell reconstitute the expression of a full-length gene via intermolecular recombination between the two AAV vector genomes…”
BackgroundSelf-citationVector engineering, strategies and targets in cancer gene therapy
Singh, V., Khan, N., & Jayandharan, G. R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00331-7 · Cited by 56
Gene therapy in retinal diseases: A review
Dhurandhar, D., Sahoo, N. K., Mariappan, I., & Narayanan, R. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3117_20 · Cited by 54
Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear
Akil, O. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107912 · Cited by 52
Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2
Stemerdink, M., García‐Bohórquez, B., Schellens, R. T. W., García‐García, G., van Wijk, E., & Millán, J. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02324-w · Cited by 49
Tickner, Z. J., & Farzan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14060554 · Cited by 45
Dual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
“Based on this study, clinical trials have been started, which will give important insights how successfully dual-AAV gene therapies perform in humans (Trapani, 2019).”
BackgroundMethodGarcía-Delgado, A. B., Valdés-Sánchez, L., Morillo-Sánchez, M. J., Ponte, B., Diaz-Corrales, F. J. J., & de la Cerda, B. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01843-z · Cited by 39
“Additional methods for retinal delivery of transcripts larger than 5 kb using the successful AAVs are theoretically feasible using dual AAV vectors, as reviewed by Trapani [80].”
MethodInfluentialNext generation therapeutics for retinal neurodegenerative diseases
Appell, M. B., Pejavar, J., Pasupathy, A., Rompicharla, S. V. K., Abbasi, S., Malmberg, K., Kolodziejski, P., & Ensign, L. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.063 · Cited by 34
Large gene delivery to the retina with AAV vectors: are we there yet?
Trapani, I., Tornabene, P., & Auricchio, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0174-4 · Cited by 32
Self-citationThe Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
Optogenetic technologies in translational cancer research
Malogolovkin, A. S., Egorov, A. D., Karabelsky, A. V., Ivanov, R. A., & Verkhusha, V. V. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.108005 · Cited by 27
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Gallego, C., Gonçalves, M. A. F. V., & Wijnholds, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00838 · Cited by 27
“AAV vectors are the most widely used tools for delivering genetic material to retinal cell types owing to their low immunogenicity and high transduction efficiencies (Trapani, 2019).”
BackgroundMethodInfluentialInner Ear Gene Therapy: An Overview from Bench to Bedside
Gadenstaetter, A. J., Krumpoeck, P. E., & Landegger, L. D. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00759-1 · Cited by 24
“Inside a cell transduced by both vectors, the two OTOF snippets can reconstitute a functional transgene for full OTOF expression [126, 127].”
New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies
Pulman, J., Sahel, J., & Dalkara, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0141 · Cited by 39
Paul, A., Collins, M. G., & Lee, H. Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.899209 · Cited by 27
“However, considering the limited carrying capacity of AAV, the cargo would have to be split into two or more vectors (Trapani, 2019; Akil, 2020).”
BackgroundGene Therapy to the Retina and the Cochlea
Crane, R., Conley, S. M., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.652215 · Cited by 25
Maf1 regulates axonal regeneration of retinal ganglion cells after injury
Chen, D., Sun, Y., Zhou, L.-Y., Yang, S., Hong, F.-Y., Liu, X., Sun, Z.-L., Huang, J., & Feng, D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113948 · Cited by 18
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2024) · Nano Research · doi:10.1007/s12274-024-6748-5 · Cited by 18
Dual AAV vectors for efficient delivery of large transgenes
Mittas, D. M., Riedmayr, L. M., Gavrilov, Z., Weber, V. J., Otify, D. Y., Mehlfeld, V., Szalontai, B., Ucambarlic, E., Gandor, C. L. A., Heigl, T., et al. (2025) · Nature Protocols · doi:10.1038/s41596-025-01243-8 · Cited by 20
Shamshad, A., Kang, C., Jenny, L. A., Persad‐Paisley, E. M., & Tsang, S. H. (2023) · Vision Research · doi:10.1016/j.visres.2023.108258 · Cited by 18
Ferreira, M. V., Fernandes, S., Almeida, A. I., Neto, S., Mendes, J. P., Silva, R. J. S., Peixoto, C., & Coroadinha, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310524 · Cited by 20
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 19
“An alternative way to deliver large genes via AAV is to create double vectors [17].”
Mutation-independent therapies for retinal diseases: focus on gene-based approaches
Carrella, S., Indrieri, A., Franco, B., & Banfi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.588234 · Cited by 14
“Another problem is that AAV particles can package only up to about 4.7 kilobases of DNA, which represent a serious obstacle to the delivery of larger genes (Trapani, 2018, 2019).”
BackgroundInfluentialGene therapy: an alternative to treat Alzheimer’s disease
Doshi, V., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02873-z · Cited by 15
“Moreover, recent advancements in gene therapy have devised the need to deliver larger cargos for cell targeting, which gets difficult mainly in the case of AAV due to its limited carrying capacity (Paul et al., 2022; Trapani, 2019).”
Retinal Ciliopathies and Potential Gene Therapies: A Focus on Human iPSC-Derived Organoid Models
McDonald, A. J., & Wijnholds, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052887 · Cited by 19
“Following transcription of the sequence on the concatemerized DNA, the ITR junction is spliced out, resulting in the full-length mRNA of the desired gene (Figure 2A) [130,131].”
MethodAdvances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review
Jain, R., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.69895 · Cited by 24
Toutounchian, S., Ahmadbeigi, N., & Mansouri, V. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0022 · Cited by 10
“129,130 In the next generations, several strategies have been explored to circumvent the problem of limited capacity AAV, and today even the largest human genes can be transferred by this viral vector.”
Small Molecules for Enhancing the Precision and Safety of Genome Editing
Shin, S., Jang, S., & Lim, D. (2022) · Molecules · doi:10.3390/molecules27196266 · Cited by 10
Deutschmeyer, V. E., & Richter, A. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188417 · Cited by 8
Chirco, K. R., Martinez, C., & Lamba, D. A. (2023) · Vision Research · doi:10.1016/j.visres.2023.108257 · Cited by 9
Peek, J. L., Rosales, A., Qi, J., Feleke, L., Menshikh, A., Welch, R., Woodard, L. E., Asokan, A., & Wilson, M. H. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201736 · Cited by 1
Rationale for haploinsufficiency correction therapy in neurofibromatosis type 1
Frost, M., Serra, E., Viskochil, D. H., Korf, B. R., Mattson-Hoss, M. K., Croston, G. E., & Sarnoff, H. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2022.14 · Cited by 6
Genetic frontiers: Exploring the latest strategies in gene delivery
Quadir, S. S., Choudhary, D., Singh, S., Choudhary, D. K., Chen, M., & Joshi, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106316 · Cited by 8
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
“Other multi-AAV approaches have been developed to improve reconstitution efficiency (Tornabene and Trapani 2020) demonstrating early clinical potential, particularly for retinal diseases (Trapani et al. 2014, Trapani 2019).”
Eyes shut homolog (EYS): Connecting molecule to disease
Marques, J. P., Sousa, I. S., Patrício, D., Simões, B. F., Chukwunalu, O., Zeitz, C., Audo, I. S., Collin, R. W. J., Quinn, P. M. J., Ambrósio, A. F., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101391 · Cited by 6
Wang, H., Tang, X., Pan, X., Tang, H., Gao, J., & Li, Q. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.02.013 · Cited by 4
Vectors in gene therapy: Benefit for glioblastoma patients
Carver, K., Negrete, D., Waterman, M., & Daddacha, W. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822527-1.00011-3 · Cited by 3
Biomedical nanobubbles and opportunities for microfluidics
Paknahad, A. A., Kerr, L., Wong, D. A., Kolios, M. C., & Tsai, S. S. H. (2023) · doi:10.32920/24026673.v1 · Cited by 3
Immune cell dynamics and cytokine regulation in cornea and transplantation
Sharma, A., Aiyan, A. A., & Kishore, U. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847174 · Cited by 1
“…investigations utilizing murine models, rabbits, and non-human primates suggest that engineered capsid variants, such as AAVv128, outperform conventional serotypes in terms of both ef fi cacy and tissue speci fi city, thereby representing a considerable advancement in retinal gene therapy (184, 185).”
A New Mouse Model for Usher Syndrome Crossing Kunming Mice with CBA/J Mice
Li, S., Jiang, Y., Zhang, L., Yan, W., Wei, D., Zhang, M., Zhu, B., Chen, T., Wang, X., Zhang, Z., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148562 · Cited by 2
Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyen, P.-A. T., Nguyen, T.-V., & Park, S. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00739-5 · Cited by 4
“GT uses VVs as delivery systems to introduce therapeutic genes into target cells and has two main applications: (Trapani 2019).”
Gene Therapy for Corneal Diseases
Bhujel, B., Eah, K. S., Kang, S. S., Chung, H. S., & Kim, J. Y. (2026) · BioTech · doi:10.3390/biotech15040080 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
The predawn dilemma in adeno-associated virus-based gene therapies for hereditary deafness
Zhou, J., Deng, D., Gan, C., Du, J., & Zhao, Y. (2025) · American Journal of Stem Cells · doi:10.62347/fesn5062 · Cited by 2
“Furthermore, split-AAV strategies can be divided into overlapping, trans-splicing and hybrid dual vectors to separate AAV vectors to deliver the target gene [9, 64, 65].”
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Viral and Nonviral Drug Delivery Systems for Medical Health Care: An Overview
Ghosh, A., Gouda, S., Kerry, R. G., Das, G., & Patra, J. K. (2020) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-39246-8_2 · Cited by 1
Innate Immunity and the Retinal Pigment Epithelium in Gene Therapy for Inherited Retinal Disorders
Casey, G. A. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-px5t-6n74
Application of Gene Therapy for Treatment of Atrial Fibrillation
Sequeira, L. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3543
Kwiatek, M., Michalski, A., Abramowicz, K., Rutyna, P., Wasiak, M., Reichert, M., & Lisowski, L. (2023) · Lekarz Wojskowy · doi:10.53301/lw/156374
Gene Therapy for Neurodegeneration in Glaucoma
Karl, J. J., & Tseng, H. C. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_21
Modification chimique d’AAV pour la thérapie génique
Leray, A. (2021) · theses.fr (ABES) · doi:10.70675/c33b1ba2z6c22z40e1z9a98z3ed26b698b7a
Wang, Z., Zhou, L., & Ming, L. (2026) · Gene · doi:10.1016/j.gene.2026.150161
Ren, G., Qin, X., Li, Y. M., Fan, W., Luo, W., Cao, Y., Wang, Y., Zhou, Y., & Liang, C. (2026) · Molecules · doi:10.3390/molecules31091417
“Gene replacement therapy using adeno-associated virus (AAV) vectors offers a promising therapeutic approach for BCD [12]. rAAV-hCYP4V2 is a gene therapy product under development based on AAV vectors, designed to deliver the functional CYP4V2 gene to retinal cells via a single administration,…”
WWOX in brain development and disease: Molecular mechanisms and therapeutic opportunities
Obeid, M., Wang, J., Abudiab, B., Akkawi, R., & Aqeilan, R. I. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107446 · Cited by 1
An intersectional expression platform for gene complementation using RNA-fragment end joining (REJ)Preprint
Bachmann, L. C., Hsu, R. H., Hermann, K. J., Williams, C. E., Farman, R. L., Criales, N., Clark, C., Kramer, S., Pérez, C. T., Randles, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.13.751279
Antioxidant Strategies for Inherited Retinal Degenerations in the Era of Gene Therapy
Yang, Y., Chen, Q., Zeng, J., Liang, L., Tao, Z., She, K., Ren, C., & Lu, F. (2026) · Antioxidants · doi:10.3390/antiox15101229
“In addition, achieving sufficient co-transduction with multiple vector components may require greater overall vector exposure [51,54], potentially increasing dose-related AAV immune and inflammatory responses [55].”
Metadata
- Authors
- Trapani, I.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Trapani, Ivana
- ORCID
- Trapani, Ivana
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-04-09
- Volume
- 10
- Issue
- 4
- Pages
- 287
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6523333
- OpenAlex
- W2939601796
- Cited by
- 73
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 4
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Università degli Studi di Napoli Federico II (STAR programme)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, gene therapy, inherited retinal disease, photoreceptors, retinal pigment epithelium
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Photoreceptor Cells, Retina, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.